论文部分内容阅读
目的观察依那普利联合人胰岛素治疗糖尿病肾病对患者血清及尿液IL-18、MCP-1水平的影响。方法将糖尿病肾病患者220例随机分为试验组和对照组各110例。2组患者均给予常规对症治疗,试验组额外给予依那普利联合人胰岛素治疗。比较2组患者治疗前后血清及尿液IL-18和MCP-1水平变化。结果治疗后2组患者血清及尿液IL-18和CMP-1水平均低于治疗前,且试验组明显低于对照组,差异均有统计学意义(P<0.05)。结论依那普利联合人胰岛素治疗糖尿病肾病可显著降低患者血清及尿液IL-18、MCP-1水平。
Objective To observe the effect of enalaprol combined with insulin on diabetic nephropathy on serum and urine IL-18 and MCP-1 levels. Methods 220 patients with diabetic nephropathy were randomly divided into experimental group and control group of 110 cases. Patients in both groups were given conventional symptomatic treatment, and the experimental group was additionally given enalapril combined with insulin therapy. The levels of IL-18 and MCP-1 in serum and urine of two groups before and after treatment were compared. Results The levels of IL-18 and CMP-1 in serum and urine of two groups after treatment were lower than those before treatment, and the levels of IL-18 and CMP-1 in the experimental group were significantly lower than those in the control group (P <0.05). Conclusion Enalaprol combined with insulin treatment of diabetic nephropathy can significantly reduce serum and urine IL-18, MCP-1 levels.